Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Phase 1/2 Completed 12 enrolled Starpharma Pty Ltd National Institute of Allergy and Infectious Diseases (NIAID) · collab

NaSingle-groupOpen-labelTreatment

Summary

To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.

Timeline

Start: 2008-08
Primary completion: 2009-03
Completion: 2009-03

Publications

Background Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPL7013	Other / unclassified	3 %	Other

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Summary

Timeline

Publications

Drugs

Indications